COMMUNIQUÉS West-GlobeNewswire
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
17/02/2026 -
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
17/02/2026 -
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
17/02/2026 -
MediWound to Present at Upcoming Investor Conferences
17/02/2026 -
Prof. Lalith Kumar Shiyam Sundar, LMU Hospital Munich, received the ICPO Research Grant for “AI-driven Advancements in Precision Oncology”
17/02/2026 -
CorVel Earns Sixth Consecutive Great Place To Work® Certification™, Reflecting Continued Investment in Employees and Innovation
17/02/2026 -
Lifecore Biomedical to Participate at DCAT Week 2026
17/02/2026 -
Kraig Biocraft Laboratories Activates First Wave of 2026 Production Program
17/02/2026 -
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
17/02/2026 -
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
17/02/2026 -
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
17/02/2026 -
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
17/02/2026 -
BioCryst to Present at Upcoming Investor Conference
17/02/2026 -
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
17/02/2026 -
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
17/02/2026 -
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
17/02/2026 -
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17/02/2026 -
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
17/02/2026 -
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
17/02/2026
Pages